Start-Up Previews (07/2010)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Alzheimer's Start-Ups Face A Discovery And Clinical Crossroads," features profiles of AlzProtect, Axerion Therapeutics, Cognition Therapeutics and Galantos Pharma. "The Future of Laparoscopy: Single Incision, NOTES And Robots," features profiles of EndoControl, Ovesco Endoscopy, SurgiQuest and Virtual Incision. Plus these Start-Ups Across Health Care: Antabio, Beta-Stim, CMP Therapeutics, Elixir Medical, Kerecis, Optivia Biotechnology, Quanterix and reinnervate.
You may also be interested in...
Elixir Medical Corp.
Elixir Medical Corp. aims to address the shortcomings of current drug-eluting stents, such as late stent thrombosis, dual antiplatelet therapy duration and better efficacy in more complex disease. Elixir's technology innovations include what it describes as the thinnest durable biocompatible polymer coating, an ultra-thin biodegradable polymer coating and a fully biodegradable drug eluting stent.
CMP Therapeutics Ltd.
Chitin may be the second most common molecule on earth. It could be the source of a treatment for the common cold, too. So hope investors in CMP Therapeutics Ltd., which is developing a micronized nose-spray version of the polysaccharide chitin. The company is also using chitin as the basis for programs in novel allergy and asthma therapies, vaccine adjuvants, and nutritional products.
Cognition Therapeutics Inc.
Using proprietary assays, Cognition Therapeutics Inc. has discovered small-molecule, highly brain-penetrable drugs that block soluble toxic amyloid beta oligomers in their reactive form, rather than target amyloid beta plaque or expression of the monomer building blocks.